CombiMatrix, Universal Diagnostic Laboratories Announce Agreement
News Aug 11, 2016
CombiMatrix Corporation has announced that Universal Diagnostic Laboratories will market and distribute CombiMatrix's chromosomal microarray miscarriage analysis test for the evaluation of multiple pregnancy loss in both Northern and Southern California. Terms of the agreement were not disclosed.
“This is another example of leveraging channel partners to augment our direct sales team's efforts in expanding the distribution of our tests,” said Mark McDonough, President and Chief Executive Officer of CombiMatrix. “Our miscarriage analysis test is now more accessible to women in our home state of California. We are pleased to partner with Universal Diagnostics Laboratories, which shares our commitment to high-touch, personalized service and excellent turnaround times.”
“This agreement demonstrates execution on a key aspect of our business strategy by expanding our portfolio of molecular diagnostics focused on women's health,” said Michael Mosunic, President and Chief Operating Officer of Universal Diagnostic Laboratories.
“Importantly, this test provides valuable information to women and their families about the reasons behind multiple miscarriages. We are particularly excited about the CombiMatrix test as chromosomal microarray analysis has shown to have superior diagnostic attributes over karyotyping for recurrent pregnancy loss.”
A New, Streamlined Approach to Diagnosing and Treating Bowel CancerNews
Researchers at the South Australian Health and Medical Research Institute (SAHMRI) and the University of Adelaide have discovered a faster, more cost-effective way to determine which DNA mutations cause human bowel cancer.READ MORE
New Rapid-fire Method Using Pathology Images & Tumor Data May Help Guide Cancer TherapiesNews
By combining data on pathology images of 13 types of cancer and correlating that with clinical and genomic data, researchers are able to identify tumor-infiltrating lymphocytes, which will enable cancer specialists to generate tumor-immune information from routinely gathered pathology slides.READ MORE
A Novel Point-of-Care Assay Developed for Hepatitis CNews
Scientists from the Institut Pasteur and Inserm have developed and validated a rapid, reliable, point-of-care HCV assay.READ MORE